Today’s Short Interest Alert: Will Vital Therapies Incorporated (NASDAQ:VTL) Run Out of Steam Soon? Short Interest Is Down

November 21, 2016 - By Vivian Park   ·   0 Comments

Today's Short Interest Alert: Will Vital Therapies Incorporated (NASDAQ:VTL) Run Out of Steam Soon? Short Interest Is Down

The stock of Vital Therapies Incorporated (NASDAQ:VTL) registered a decrease of 0.76% in short interest. VTL’s total short interest was 1.75 million shares in November as published by FINRA. Its down 0.76% from 1.77 million shares, reported previously. With 48,700 shares average volume, it will take short sellers 36 days to cover their VTL’s short positions. The short interest to Vital Therapies Incorporated’s float is 8.22%. The stock closed at $6.1 during the last session. It is down 33.26% since April 19, 2016 and is downtrending. It has underperformed by 37.12% the S&P500.

Vital Therapies, Inc. is a biotherapeutic company. The company has a market cap of $187.81 million. The Firm is focused on developing a human hepatic cell treatment targeting acute forms of liver failure. It currently has negative earnings. The Company’s product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q2. Its down 0.77, from 1.58 in 2016Q1. The ratio dived, as 8 funds sold all Vital Therapies Inc shares owned while 11 reduced positions. 7 funds bought stakes while 23 increased positions. They now own 8.18 million shares or 10.33% less from 9.13 million shares in 2016Q1.
Kcg last reported 0% of its portfolio in the stock. Deutsche Bank Ag reported 7,356 shares or 0% of all its holdings. Tower Cap Llc (Trc) holds 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 4,439 shares. Blackrock Management Limited Com has invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Botty Limited Liability holds 0.11% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 30,000 shares. Voya Invest Mgmt Limited Co, a Georgia-based fund reported 11,533 shares. Vanguard Group accumulated 0% or 777,809 shares. Tiaa Cref Inv Lc reported 81,163 shares or 0% of all its holdings. Bankshares Of America De holds 8,648 shares or 0% of its portfolio. Parametric Port Associates Lc, a Washington-based fund reported 12,608 shares. Geode Management Ltd last reported 0% of its portfolio in the stock. Hightower Advisors Ltd Limited Liability Company has 10,000 shares for 0% of their US portfolio. Barclays Public Ltd Co last reported 265 shares in the company. California State Teachers Retirement Systems accumulated 49,657 shares or 0% of the stock. Jpmorgan Chase & holds 940 shares or 0% of its portfolio.

Insider Transactions: Since August 11, 2016, the stock had 1 buy, and 0 insider sales for $699,999 net activity. 118,243 Vital Therapies Inc (NASDAQ:VTL) shares with value of $699,999 were bought by Hasnain Faheem.

Vital Therapies Inc (NASDAQ:VTL) Ratings Coverage

Out of 6 analysts covering Vital Therapies Inc (NASDAQ:VTL), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. Vital Therapies Inc has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Suntrust Robinson given on Monday, August 24. SunTrust downgraded the stock to “Neutral” rating in Tuesday, September 29 report. BTIG Research initiated the stock with “Buy” rating in Friday, August 7 report. Credit Suisse downgraded Vital Therapies Inc (NASDAQ:VTL) rating on Monday, August 24. Credit Suisse has “Neutral” rating and $9 price target. The stock has “Neutral” rating given by Suntrust Robinson on Tuesday, September 29. The rating was downgraded by SunTrust on Monday, August 24 to “Buy”. The firm has “Neutral” rating given on Monday, October 26 by BTIG Research. The rating was downgraded by William Blair to “Outperform” on Monday, August 24. Canaccord Genuity maintained it with “Buy” rating and $8.0 target price in Monday, August 24 report. Credit Suisse reinitiated Vital Therapies Inc (NASDAQ:VTL) on Monday, August 10 with “Outperform” rating.

VTL Company Profile

Vital Therapies, Inc., incorporated on January 13, 2004, is a biotherapeutic company. The Firm is focused on developing a human hepatic cell treatment targeting acute forms of liver failure. The Company’s product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Firm initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges containing its human liver-derived C3A cells attached to a reusable delivery device using customized disposable tubing sets. The delivery device is based on a cardio-pulmonary bypass machine, which it has configured for the ELAD System treatment. This unit and customized disposable sets are attached to the ELAD C3A cell cartridges where the patient’s blood plasma is treated by its VTL C3A cells before being returned to the patient. Treatment will generally consist of a single session of continuous allogeneic cellular therapy.

More recent Vital Therapies Inc (NASDAQ:VTL) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on April 16, 2014. Also Quotes.Wsj.com published the news titled: “News Vital Therapies Inc.VTL” on November 24, 2013. Globenewswire.com‘s news article titled: “Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 …” with publication date: November 19, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>